Retatrutide vs Semaglutide
An evidence-first, side-by-side comparison. We compare what the research supports — not marketing claims.
Last updated
Evidence grade
Human RCT
Human RCT
What that means
Randomized controlled trials in humans — the strongest evidence we grade.
Randomized controlled trials in humans — the strongest evidence we grade.
Status
In clinical trials
FDA-approved
Mechanism
Retatrutide hits three receptors at once: GLP-1 and GIP — the two incretin pathways tirzepatide already targets — plus the glucagon receptor. The glucagon arm is the differentiator: glucagon-receptor activation raises energy expenditure and drives hepatic fat use, so the theory is that you add a "burn" lever on top of the appetite-suppression incretin levers. That third axis is also why the compound is watched closely on heart rate and glycemic control. Whether the triple mechanism is genuinely better than dual agonism, rather than just dosed higher, is exactly what the phase 3 program has to settle.
Semaglutide is a long-acting GLP-1 receptor agonist. It mimics the gut incretin hormone GLP-1: slowing gastric emptying, acting on appetite centers in the hypothalamus to reduce hunger and food intake, and enhancing glucose-dependent insulin secretion. The appetite effect is the one that drives the weight loss — people simply eat less and feel full sooner. Structural modifications (a fatty-acid chain that binds albumin) give it a long enough half-life for once-weekly injection, and an oral formulation (Rybelsus) exists for the diabetes indication.
Weight-loss data
Up to ~24% mean body-weight reduction at the 12 mg dose over 48 weeks (phase 2, Jastreboff 2023)
Mean ~14.9% body-weight reduction at 2.4 mg/week over 68 weeks (STEP 1, Wilding 2021)
Goals
Fat loss, Body composition, Visceral fat reduction
Fat loss, Body composition, Visceral fat reduction
Key risks
- Not approved by any regulator — investigational, phase 2 only; long-term safety is unknown
- Dose-dependent GI effects (nausea, vomiting, diarrhea, constipation) are the most common adverse events
- Dose-dependent increases in heart rate were observed — a signal the glucagon-agonist mechanism makes worth watching
- Boxed warning: in rodents, GLP-1 agonists caused thyroid C-cell tumors; contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Human relevance is unestablished but the contraindication stands
- GI effects are very common: nausea, vomiting, diarrhea, constipation — usually dose-dependent and worst during dose escalation
- Reports of acute pancreatitis; discontinue if suspected
Regulatory
Under active investigation in human trials; not yet approved.
Approved by the FDA for one or more human indications.